SGLT2 inhibitors for heart failure: effect on inflammation
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether a type of diabetes medicine called SGLT2 inhibitors can lower inflammation and stress markers in people with heart failure. It may help reduce damage to the heart and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have heart failure with symptoms like shortness of breath or fatigue (NYHA class II–IV).
- You are already taking standard heart failure medications (like ACE inhibitors, beta blockers, or diuretics).
- You do not have other serious heart conditions or infections that could affect inflammation.
- You are not pregnant, breastfeeding, or have cancer, thyroid problems, or advanced kidney disease (eGFR below 20).
- You can communicate and understand the study information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests a medication called sotagliflozin for people who have both type 1 diabetes and heart failure symptoms. The goal is to see if it can improve how you feel and manage your heart and diabetes.
This study looks at whether a type of diabetes medicine called SGLT2 inhibitors (also known as flozins) can help protect the heart and kidneys in people with both heart failure with preserved pumping function and moderate chronic kidney disease, with or without diabetes.
This study tests whether a type of diabetes medication called an SGLT2 inhibitor can improve the structure and function of the heart's left atrium in people with type 2 diabetes. It may help prevent heart problems in the future.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.